Characterization of Treatment Response Outcomes in Chronic Pulmonary Aspergillosis: CPAnet Definitions Versus the Existing Criteria
- PMID: 37291204
- DOI: 10.1007/s11046-023-00751-z
Characterization of Treatment Response Outcomes in Chronic Pulmonary Aspergillosis: CPAnet Definitions Versus the Existing Criteria
Abstract
Background: The chronic pulmonary aspergillosis network (CPAnet) has recently proposed definitions for treatment outcomes in CPA. However, these definitions need to be validated. Herein, we evaluate the agreement between the existing and the CPAnet definitions for response assessment.
Methods: We enrolled consecutive treatment-naïve CPA subjects (between January 2021 and June 2021) who received six months of itraconazole therapy and followed them for an additional six months after treatment discontinuation. We retrospectively applied the CPAnet criteria and compared the agreement between the existing and the CPAnet criteria for response assessment (primary objective). We also assessed if adding weight loss (> 5% from baseline) as a component improved the performance of the CPAnet criteria.
Results: We included 43 (mean age, 47.4 years) CPA subjects. The existing and the CPAnet criteria categorized 29 (67.4%) and 30 (69.8%) subjects as treatment success, respectively, at treatment completion. There was substantial (kappa = 0.73; p < 0.0001) agreement between the two definitions. However, both criteria did not identify eight subjects requiring treatment re-initiation within three months. There was an increment in the sensitivity of both criteria (by 36%) for identifying treatment failure after incorporating ≥ 5% weight loss as an element of worsening.
Conclusion: The CPAnet definitions correctly categorized treatment outcomes in most cases of CPA. The addition of weight change would further enhance the performance of the CPAnet treatment outcome definitions.
Keywords: CCPA; Fungal-ball; Post-tuberculosis lung disease; Subacute invasive aspergillosis.
© 2023. The Author(s), under exclusive licence to Springer Nature B.V.
Similar articles
-
CPAnet Registry-An International Chronic Pulmonary Aspergillosis Registry.J Fungi (Basel). 2020 Jun 29;6(3):96. doi: 10.3390/jof6030096. J Fungi (Basel). 2020. PMID: 32610566 Free PMC article.
-
A CPAnet consensus statement on research priorities for chronic pulmonary aspergillosis: a neglected fungal infection that requires attention.J Antimicrob Chemother. 2018 Feb 1;73(2):280-286. doi: 10.1093/jac/dkx390. J Antimicrob Chemother. 2018. PMID: 29126309 Review.
-
Treatment outcome definitions in chronic pulmonary aspergillosis: a CPAnet consensus statement.Eur Respir J. 2022 Jun 9;59(6):2102950. doi: 10.1183/13993003.02950-2021. Print 2022 Jun. Eur Respir J. 2022. PMID: 35236726 No abstract available.
-
Clinical features and outcome of patients with chronic pulmonary aspergillosis in China: A retrospective, observational study.J Mycol Med. 2020 Dec;30(4):101041. doi: 10.1016/j.mycmed.2020.101041. Epub 2020 Aug 28. J Mycol Med. 2020. PMID: 32950379
-
An overview of the available treatments for chronic cavitary pulmonary aspergillosis.Expert Rev Respir Med. 2020 Jul;14(7):715-727. doi: 10.1080/17476348.2020.1750956. Epub 2020 Apr 20. Expert Rev Respir Med. 2020. PMID: 32249630 Review.
Cited by
-
The minimal important difference of one-minute-sit-to-stand test in subjects with chronic pulmonary aspergillosis.Lung India. 2024 Sep 1;41(5):353-356. doi: 10.4103/lungindia.lungindia_168_24. Epub 2024 Aug 31. Lung India. 2024. PMID: 39215977 Free PMC article.
-
Chronic pulmonary aspergillosis: comprehensive insights into epidemiology, treatment, and unresolved challenges.Ther Adv Infect Dis. 2024 Jun 18;11:20499361241253751. doi: 10.1177/20499361241253751. eCollection 2024 Jan-Dec. Ther Adv Infect Dis. 2024. PMID: 38899061 Free PMC article. Review.
References
-
- Denning DW, Pleuvry A, Cole DC. Global burden of chronic pulmonary aspergillosis as a sequel to pulmonary tuberculosis. Bull World Health Organ. 2011;89(12):864–72. https://doi.org/10.2471/blt.11.089441 . - DOI - PubMed - PMC
-
- Denning DW, Cole DC, Ray A. New estimation of the prevalence of chronic pulmonary aspergillosis (CPA) related to pulmonary TB—a revised burden for India. IJID Reg. 2023;6:7–14. https://doi.org/10.1016/j.ijregi.2022.11.005 . - DOI - PubMed
-
- Ocansey BK, Otoo B, Gbadamosi H, Afriyie-Mensah JS, Opintan JA, Kosmidis C, et al. Importance of Aspergillus-specific antibody screening for diagnosis of chronic pulmonary aspergillosis after tuberculosis treatment: a prospective follow-up study in Ghana. J Fungi (Basel). 2022. https://doi.org/10.3390/jof9010026 . - DOI - PubMed
-
- de Oliveira VF, Viana JA, Sawamura MVY, Magri A, Nathan Costa A, Abdala E, et al. Sensitivity of antigen, serology, and microbiology assays for diagnosis of the subtypes of chronic pulmonary aspergillosis at a teaching hospital in São Paulo. Brazil Am J Trop Med Hyg. 2023;108(1):22–6. https://doi.org/10.4269/ajtmh.22-0412 . - DOI - PubMed
-
- Sehgal IS, Dhooria S, Muthu V, Rudramurthy SM, Prasad KT, Chakrabarti A, et al. Identification of distinct immunophenotypes in chronic pulmonary aspergillosis using cluster analysis. Mycoses. 2023;66(4):299–303. https://doi.org/10.1111/myc.13553 . - DOI - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources